Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs TPI 287 (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions
- Acronyms TPI-287-4RT
- 13 Apr 2020 Status changed from active, no longer recruiting to completed.
- 11 Nov 2019 Results assessing the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease published in the JAMA Neurology
- 01 May 2018 Planned End Date changed from 1 Aug 2017 to 1 Mar 2019.